Process for purification of monoclonal antibody expressed in transgenic Lemna plant extract using dextran-coated charcoal and hexamer peptide affinity resin

Naik, Amith D.; Menegatti, Stefano; Reese, Hannah; Gurgel, Patrick V.; Carbonell, Ruben G.

doi:10.1016/j.chroma.2012.08.043

Cited by 33 publications

(18 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In principle, most plantibodies are expressed in tobacco ( N. tabacum or N. benthamiana ), but there are also production systems in Lemna minor (duckweed) (209–211), rice cell culture (212), Arabidopsis thaliana seeds (213, 214), Medicago sativa (alfalfa) (215), lettuce (216), and maize (217). HIV-1 neutralizing antibody 2G12 was expressed in the endosperm of maize and showed similar or even better neutralizing properties as its CHO-derived counterpart (218).…”

Section: Transgenic Organismsmentioning

confidence: 99%

Expression of Recombinant Antibodies

Frenzel¹,

Hust²,

Schirrmann³

2013

Front. Immunol.

274

220

View full text Add to dashboard Cite

Recombinant antibodies are highly specific detection probes in research, diagnostics, and have emerged over the last two decades as the fastest growing class of therapeutic proteins. Antibody generation has been dramatically accelerated by in vitro selection systems, particularly phage display. An increasing variety of recombinant production systems have been developed, ranging from Gram-negative and positive bacteria, yeasts and filamentous fungi, insect cell lines, mammalian cells to transgenic plants and animals. Currently, almost all therapeutic antibodies are still produced in mammalian cell lines in order to reduce the risk of immunogenicity due to altered, non-human glycosylation patterns. However, recent developments of glycosylation-engineered yeast, insect cell lines, and transgenic plants are promising to obtain antibodies with “human-like” post-translational modifications. Furthermore, smaller antibody fragments including bispecific antibodies without any glycosylation are successfully produced in bacteria and have advanced to clinical testing. The first therapeutic antibody products from a non-mammalian source can be expected in coming next years. In this review, we focus on current antibody production systems including their usability for different applications.

show abstract

Section: Transgenic Organismsmentioning

confidence: 99%

Expression of Recombinant Antibodies

Frenzel¹,

Hust²,

Schirrmann³

2013

Front. Immunol.

274

220

View full text Add to dashboard Cite

show abstract

“…; Naik et al . ). Additionally, duckweed can be used as a dietary supplement for humans and animals because of its high nutritional value (Bhanthumnavin & Mcgarry ).…”

Section: Introductionmentioning

confidence: 97%

“…Several duckweed species, e.g. Lemna minor, have been engineered to produce antigens, monoclonal antibodies and exogenous enzymes (Sun et al 2007;Ko et al 2011;Naik et al 2012). Additionally, duckweed can be used as a dietary supplement for humans and animals because of its high nutritional value (Bhanthumnavin & Mcgarry 1971).…”

Section: Introductionmentioning

confidence: 99%

Survey of duckweed diversity in Lake Chao and total fatty acid, triacylglycerol, profiles of representative strains

Tang

et al. 2015

Plant Biol J

View full text Add to dashboard Cite

Lemnaceae (duckweeds) are widely distributed aquatic flowering plants. Their high growth rate, starch content and suitability for bioremediation make them potential feedstock for biofuels. However, few natural duckweed resources have been investigated in China, and there is no information about total fatty acid (TFA) and triacylglycerol (TAG) composition of duckweeds from China. Here, the genetic diversity of a natural duckweed population collected from Lake Chao, China, was investigated using multilocus sequence typing (MLST). The 54 strains were categorised into four species in four genera, representing 12 distinct sequence types. Strains representing Lemna aequinoctialis and Spirodela polyrhiza were predominant. Interestingly, a surprisingly high degree of genetic diversification within L. aequinoctialis was observed. The four duckweed species revealed a uniform fatty acid composition, with three fatty acids, palmitic acid, linoleic acid and linolenic acid, accounting for more than 80% of the TFA. The TFA in biomass varied among species, ranging from 1.05% (of dry weight, DW) for L. punctata and S. polyrhiza to 1.62% for Wolffia globosa. The four duckweed species contained similar TAG contents, 0.02% mg · DW(-1). The fatty acid profiles of TAG were different from those of TFA, and also varied among the four species. The survey investigated the genetic diversity of duckweeds from Lake Chao, and provides an initial insight into TFA and TAG of four duckweed species, indicating that intraspecific and interspecific variations exist in the content and composition of both TFA and TAG in comparison with other studies.

show abstract

“…As most so-called plantibodies are expressed in tobacco plants, several other species have been used as expression system such as Arabidopsis thaliana [256], duckweed [257,258], lettuce [259], maize [260], Medicago sativa [261], and rice cell culture [262].…”

Section: Plantsmentioning

confidence: 99%

Emerging Alternative Production Systems

Sommer

Laux

Frenzel

et al. 2014

Handbook of Therapeutic Antibodies

View full text Add to dashboard Cite

The market of recombinant protein pharmaceuticals is growing rapidly. Among those, recombinant antibodies are the fastest growing group and a large number of new antibody products are in clinical and preclinical development. Since most conventional cost-effective microbial expression systems are not yet applicable for the expression of fully functional immunoglobulin G (IgG) antibodies, almost all of the currently marketed therapeutic recombinant antibody products are produced from animal cell culture processes that are associated with relative high operating expenses. Thus, to make broad use of recombinant antibody therapeutics more affordable, alternative production systems with improved efficiency and reduced operating expenses are highly desirable.IgG currently is the dominant antibody format for therapeutics. As a heterotetrameric molecule with numerous disulfide bonds and several glycosylation sites IgG makes itself a challenging candidate for heterologous expression, especially in prokaryotes. Glycosylation of the fragment crystallizable (Fc) region has been shown to be essential for mediating effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [1]. Furthermore, the glycosylation pattern strongly influences the efficiency of the induction of effector functions by antibodies [2, 3]. For applications that depend on the immunological effector functions of the antibody therefore eukaryotic production systems with suitable glycosylation capabilities are necessary.Antibody fragments such as single chain fragment variable (scFv) and fragment antigen binding (Fab) are less complex and the antigen-binding activity is independent of glycosylation, which makes them qualified for prokaryotic expression systems. Certainly, these fragments are incapable of mediating immunological effector functions but for numerous applications this is not necessary or even unwanted.Besides the two traditional expression systems, Escherichia coli for antibody fragments and Chinese hamster ovarian (CHO) or myeloma cells for IgG antibodies, numerous alternative expression systems are currently under development.

show abstract

Process for purification of monoclonal antibody expressed in transgenic Lemna plant extract using dextran-coated charcoal and hexamer peptide affinity resin

Cited by 33 publications

References 28 publications

Expression of Recombinant Antibodies

Expression of Recombinant Antibodies

Survey of duckweed diversity in Lake Chao and total fatty acid, triacylglycerol, profiles of representative strains

Emerging Alternative Production Systems

Contact Info

Product

Resources

About